Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors (FLT)

This study has been completed.
National Cancer Institute, France
Information provided by (Responsible Party):
University Hospital, Caen Identifier:
First received: February 23, 2009
Last updated: August 31, 2012
Last verified: August 2012
The primary objective of this study is to assess the efficacy of the radiopharmaceutical 3'-deoxy-3'-[F-18]fluorothymidine, [F-18]FLT, a tracor of cell proliferation, using Positron Emission Tomography (PET) imaging for the tumor diagnosis and prognosis in a group of 50 patients with different type of brain tumors.[F-18]FLT PET imaging will be compared to the current used imaging techniques of MRI, spectroscopy imaging, PET imaging using [11C]MET tracer, immunohistochemical analysis and clinical parameters.

Condition Intervention
Brain Tumors
Other: FLT-PET imaging

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Assessment of [18F]FLT-PET Imaging for Diagnosis and Prognosis of Brain Tumors

Resource links provided by NLM:

Further study details as provided by University Hospital, Caen:

Primary Outcome Measures:
  • To evaluated the aggressive potential of brain tumors related to cell proliferation index measured by [18F]FLT [ Time Frame: Day 10 ]

Secondary Outcome Measures:
  • To compare the efficiency of [18F]FLT with [11C]MET [ Time Frame: Day 15 ]
  • To define relations between [18F]FLT uptake and clinical, histological and radiological parameters [ Time Frame: Day 90 ]
  • To define relations between [18F]FLT uptake and patient survival [ Time Frame: J90 ]

Enrollment: 50
Study Start Date: October 2008
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FLT-PET imaging
Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
Other: FLT-PET imaging
Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adults aged between 18 and 70 years
  • must have operable grade II, III or IV glioma, recurrent high grade glioma or brain metastases
  • KPS >= 70%
  • must have the understanding and ability to sign an informed consent document
  • must have adequate liver and kidney function
  • be male or non-pregnant, non-lactating females
  • patients who are fertile must agree to use an effective method of contraception during participation in the study
  • the following laboratory results : absolute neutrophil count >= 1500 cells/µl, platelet count >= 100000 cells/µl, SGOT <= 2.5 x ULN, serum creatinine <= 1.5 x ULN.

Exclusion Criteria:

  • contraindication to surgery
  • concomitant radio-, chemo-, or immunotherapy
  • history of significant dementia
  • known diagnosis of Human Immunodeficiency Virus (HIV) infection
  • patient with hepatitis B or C
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00850278

Caen University Hospital
Caen, France, 14033
Sponsors and Collaborators
University Hospital, Caen
National Cancer Institute, France
Principal Investigator: Jean-Sébastien Guillamo, MD, PhD University Hospital, Caen
Study Director: Jean-Michel Derlon, Pr University Hospital, Caen
  More Information

Responsible Party: University Hospital, Caen Identifier: NCT00850278     History of Changes
Other Study ID Numbers: 2007-006265-32
Study First Received: February 23, 2009
Last Updated: August 31, 2012

Keywords provided by University Hospital, Caen:
Brain tumor
tumor cell proliferation

Additional relevant MeSH terms:
Brain Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases processed this record on May 23, 2017